The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis

Osteoporosis International

Volumn 21, Issue 8, 2010, Pages 1287-1293

  Edwards, C J ^a   Williams, E ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cytokines; Interleukin 6; Osteoporosis; Rheumatoid arthritis

Indexed keywords

GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; PLACEBO; PREDNISONE; RALOXIFENE; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BODY MASS; BONE DENSITY; BONE METABOLISM; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; FRACTURE; HUMAN; INFLAMMATION; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ARTHRITIS, RHEUMATOID; BONE DENSITY CONSERVATION AGENTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; OSTEOPOROSIS; RISK FACTORS;

EID: 77954535372     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1192-7     Document Type: Review

References (58)

1. NC Walsh TN Crotti SR Goldring EM Gravallese 2005 Rheumatic diseases: the effects of inflammation on bone Immunol Rev 208 228 251 10.1111/j.0105-2896. 2005.00338.x 1:CAS:528:DC%2BD28Xks1ehsA%3D%3D 16313352
2. GS Firestein 2003 Evolving concepts of rheumatoid arthritis Nature 423 356 361 10.1038/nature01661 1:CAS:528:DC%2BD3sXjs1ynu7c%3D 12748655 (Pubitemid 40852711)
3. TR Mikuls 2003 Co-morbidity in rheumatoid arthritis Best Pract Res Clin Rheumatol 17 729 752 10.1016/S1521-6942(03)00041-X 12915155
4. A Young G Koduri 2007 Extra-articular manifestations and complications of rheumatoid arthritis Best Pract Res Clin Rheumatol 21 907 927 10.1016/j.berh.2007.05.007 17870035 (Pubitemid 47377809)
5. DH Forsblad A Larsen E Waltbrand G Kvist D Mellstrom T Saxne C Ohlsson E Nordborg H Carlsten 2003 Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis Ann Rheum Dis 62 617 623 10.1136/ard.62.7.617 (Pubitemid 36760557)
6. L Sinigaglia M Varenna G Girasole G Bianchi 2006 Epidemiology of osteoporosis in rheumatic diseases Rheum Dis Clin North Am 32 631 658 10.1016/j.rdc.2006.07.002 17288969 (Pubitemid 46590092)
7. TP van Staa P Geusens JW Bijlsma HG Leufkens C Cooper 2006 Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis Arthritis Rheum 54 3104 3112 10.1002/art.22117 17009229 (Pubitemid 44622079)
8. BA Michel DA Bloch F Wolfe JF Fries 1993 Fractures in rheumatoid arthritis: an evaluation of associated risk factors J Rheumatol 20 1666 1669 1:STN:280:DyaK2c7isFersg%3D%3D 8295176
9. H Kröger R Honkanen S Saarikoski E Alhava 1994 Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-a population based study Ann Rheum Dis 53 18 23 10.1136/ard.53.1.18 8311549 (Pubitemid 24067403)
10. NE Lane AR Pressman VL Star SR Cummings MC Nevitt 1995 Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group J Bone Miner Res 10 257 263 10.1002/jbmr.5650100212 1:STN:280:DyaK2M3nsVChtw%3D%3D 7754805
11. P Emery M Salmon 1991 The immune response. 2. Systemic mediators of inflammation Br J Hosp Med 45 164 168 1:STN:280:DyaK3M3jtVersA%3D%3D 1903078
12. GR Mundy 2007 Osteoporosis and inflammation Nutr Rev 65 S147 S151 10.1111/j.1753-4887.2007.tb00353.x 18240539
13. WB Ershler SM Harman ET Keller 1997 Immunologic aspects of osteoporosis Dev Comp Immunol 21 487 499 10.1016/S0145-305X(97)00029-3 1:STN:280: DyaK1c7isV2nsQ%3D%3D 9463782 (Pubitemid 28030862)
14. LW Moreland JR Curtis 2008 Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms Semin Arthritis Rheum 39 132 143 10.1016/j.semarthrit.2008.08.003 19022481
15. TS Kwan M Padrines S Theoleyre D Heymann Y Fortun 2004 IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology Cytokine Growth Factor Rev 15 49 60 10.1016/j.cytogfr.2003.10.005 (Pubitemid 38121290)
16. T Naka N Nishimoto T Kishimoto 2002 The paradigm of IL-6: from basic science to medicine Arthritis Res 4 Suppl 3 S233 S242 10.1186/ar565 12110143
17. JR Hooyman LJ Melton 3rd AM Nelson WM O'Fallon BL Riggs 1984 Fractures after rheumatoid arthritis. A population-based study Arthritis Rheum 27 1353 1361 10.1002/art.1780271205 1:STN:280:DyaL2M%2Fnt1elsA%3D%3D 6508860 (Pubitemid 15190899)
18. AA Deodhar AD Woolf 1996 Bone mass measurement and bone metabolism in rheumatoid arthritis: a review Br J Rheumatol 35 309 322 10.1093/rheumatology/ 35.4.309 1:STN:280:DyaK283hs12itA%3D%3D 8624634
19. K Sewell JR Schein 2001 Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects Semin Arthritis Rheum 30 288 297 10.1053/sarh.2001.16648 1:STN:280:DC%2BD3M3hsVKqug%3D%3D 11182029 (Pubitemid 32175115)
20. B Seriolo S Paolino A Sulli V Ferretti M Cutolo 2006 Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis Ann N Y Acad Sci 1069 420 427 10.1196/annals.1351.040 1:CAS:528:DC%2BD28XovF2gt7o%3D 16855169 (Pubitemid 43989885)
21. P Oelzner A Schwabe G Lehmann T Eidner S Franke G Wolf G Hein 2008 Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis Rheumatol Int 28 1143 1150 10.1007/s00296-008-0576-x 18446340
22. TV Nguyen JA Eisman PJ Kelly PN Sambrook 1996 Risk factors for osteoporotic fractures in elderly men Am J Epidemiol 144 255 263 1:STN:280:DyaK28zgt1Wntw%3D%3D 8686694
23. BL Riggs LJ Melton 3rd 1995 The worldwide problem of osteoporosis: insights afforded by epidemiology Bone 17 505S 511S 10.1016/8756-3282(95)00258-4 1:STN:280:DyaK287ks12gtg%3D%3D 8573428
24. MK Javaid RI Holt 2008 Understanding osteoporosis J Psychopharmacol 22 38 45 10.1177/0269881107087955 18477619
25. E Canalis AM Delany 2002 Mechanisms of glucocorticoid action in bone Ann N Y Acad Sci 966 73 81 10.1111/j.1749-6632.2002.tb04204.x 1:CAS:528: DC%2BD38XlvVWmsbk%3D 12114261
26. A Gough P Sambrook J Devlin A Huissoon C Njeh S Robbins T Nguyen P Emery 1998 Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis J Rheumatol 25 1282 1289 1:STN:280:DyaK1czjvFekuw%3D%3D 9676757
27. F De Benedetti N Rucci A Del Fattore B Peruzzi R Paro M Longo M Vivarelli F Muratori S Berni P Ballanti S Ferrari A Teti 2006 Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system Arthritis Rheum 54 3551 3563 10.1002/art.22175 17075861 (Pubitemid 44737167)
28. RD Devlin SV Reddy R Savino G Ciliberto GD Roodman 1998 IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures J Bone Miner Res 13 393 399 10.1359/jbmr.1998.13.3.393 1:CAS:528:DyaK1cXhvFGlsLw%3D 9525339 (Pubitemid 28146221)
29. SH Ralston 1994 Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis J Bone Miner Res 9 883 890 10.1002/jbmr.5650090614 1:CAS:528:DyaK2MXis1Gnsg%3D%3D 8079663
30. C Ding V Parameswaran R Udayan J Burgess G Jones 2008 Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study J Clin Endocrinol Metab 93 1952 1958 10.1210/jc.2007-2325 1:CAS:528:DC%2BD1cXlvFWgtrc%3D 18285417 (Pubitemid 351656543)
31. PC Heinrich I Behrmann S Haan HM Hermanns G Müller-Newen F Schaper 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation Biochem J 374 1 20 10.1042/BJ20030407 1:CAS:528:DC%2BD3sXmtF2hurs%3D 12773095 (Pubitemid 37046923)
32. M Bustamante X Nogues L Mellibovsky L Agueda S Jurado E Caceres J Blanch R Carreras A Diez-Perez D Grinberg S Balcells 2007 Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women Eur J Endocrinol 157 677 684 10.1530/EJE-07-0389 1:CAS:528:DC%2BD2sXhsValu7fO 17984249 (Pubitemid 350187386)
33. Y Ohsugi T Kishimoto 2008 The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis Expert Opin Biol Ther 8 669 681 10.1517/14712598.8.5.669 1:CAS:528:DC%2BD1cXksF2ltL0%3D 18407769 (Pubitemid 351685030)
34. B Abrahamsen V Bonnevie-Nielsen EN Ebbesen J Gram H Beck-Nielsen 2000 Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study J Bone Miner Res 15 1545 1554 10.1359/jbmr.2000.15.8.1545 1:CAS:528: DC%2BD3cXlvVSjt7s%3D 10934653
35. RD Pollak F Karmeli R Eliakim Z Ackerman K Tabb D Rachmilewitz 1998 Femoral neck osteopenia in patients with inflammatory bowel disease Am J Gastroenterol 93 1483 1490 10.1111/j.1572-0241.1998.468-q.x 1:STN:280: DyaK1cvgtFOltA%3D%3D 9732930 (Pubitemid 29075187)
36. H Tsangari DM Findlay JS Kuliwaba GJ Atkins NL Fazzalari 2004 Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck Bone 35 334 342 10.1016/j.bone.2004.02.006 1:CAS:528:DC%2BD2cXltVGjsLs%3D 15207775 (Pubitemid 38789182)
37. T Nakashima Y Kobayashi S Yamasaki A Kawakami K Eguchi H Sasaki H Sakai 2000 Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines Biochem Biophys Res Commun 275 768 775 10.1006/bbrc.2000.3379 1:CAS:528:DC%2BD3cXmtFGlsL8%3D 10973797
38. V Poli R Balena E Fattori A Markatos M Yamamoto H Tanaka G Ciliberto GA Rodan F Costantini 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion EMBO J 13 1189 1196 1:CAS:528: DyaK2cXitFGjt74%3D 8131749
39. C Jochems M Lagerquist C Håkansson C Ohlsson H Carlsten 2008 Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis Clin Exp Immunol 152 593 597 1:CAS:528:DC%2BD1cXnvVOiu74%3D 18435803
40. T Sugiyama 2001 Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis J Bone Miner Metab 19 89 96 10.1007/s007740170046 1:CAS:528:DC%2BD3MXktlektL8%3D 11281165 (Pubitemid 32290704)
41. W Zhao Y Liu CM Cahill W Yang JT Rogers X Huang 2009 The role of T cells in osteoporosis, an update Int J Clin Exp Pathol 2 544 552
42. XH Liu A Kirschenbaum S Yao AC Levine 2005 Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system Endocrinology 146 1991 1998 10.1210/en.2004-1167 1:CAS:528:DC%2BD2MXis1yqurY%3D 15618359 (Pubitemid 40396909)
43. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid P Delmas HB Zoog M Austin A Wang S Kutliek S Adami J Zanchetta C Libanati S Siddhanti C Christiansen 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 10.1056/NEJMoa0809493 1:CAS:528:DC%2BD1MXhtVWls7nF 19671655
44. O Di Munno SA Delle M Rossini S Adami 2005 Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis Clin Exp Rheumatol 23 137 144 15895881
45. American College of Rheumatology 2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis Arthritis Rheum 44 1496 1503 10.1002/1529-0131(200107)44:7<1496::AID- ART271>3.0.CO;2-5 (Pubitemid 32642211)
46. P Bergmann J-J Body S Boonen Y Boutsen J-P Devogelaer S Goemaere J-M Kaufman J-Y Reginster V Gangji 2009 Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club Int J Clin Pract 63 19 26 10.1111/j.1742-1241.2008.01911.x 1:CAS:528:DC%2BC3cXktFGnsLc%3D 19125989
47. U Lange U Illgner J Teichmann H Schleenbecker 2004 Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study Int J Clin Pharmacol Res 24 33 38 1:CAS:528:DC%2BD2MXisVagsrc%3D 15689049
48. WF Lems MC Lodder P Lips JW Bijlsma P Geusens N Schrameijer CM van de Ven BA Dijkmans 2006 Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial Osteoporos Int 17 716 723 10.1007/s00198-005-0037-2 1:CAS:528:DC%2BD28XjsVertro%3D 16463007
49. K Yamamoto S Yoshino G Shue M Nagashima 2006 Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models Rheumatol Int 26 627 632 10.1007/s00296-005-0042-y 1:CAS:528:DC%2BD28XjsVeksL0%3D 16133581
50. T Mawatari H Miura S Hamai T Shuto Y Nakashima K Okazaki N Kinukawa S Sakai PF Hoffmann Y Iwamoto TM Keaveny 2008 Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial Arthritis Rheum 58 3340 3349 10.1002/art.23988 1:CAS:528:DC%2BD1cXhsV2hs7nO 18975334
51. SB Cohen RK Dore NE Lane PA Ory CG Peterfy JT Sharp D van der Heijde L Zhou W Tsuji R Newmark 2008 Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis Rheum 58 1299 1309 10.1002/art.23417 1:CAS:528: DC%2BD1cXms1ehu70%3D 18438830 (Pubitemid 351705919)
52. KA Sutherland HL Rogers D Tosh MJ Rogers 2009 RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro Arthritis Res Ther 11 R58 10.1186/ar2681 19405951
53. U Lange J Teichmann U Müller-Ladner J Strunk 2005 Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study Rheumatology (Oxford) 44 1546 1548 10.1093/rheumatology/kei082 1:CAS:528:DC%2BD2MXht1GltrzI (Pubitemid 41742473)
54. H Marotte B Pallot-Prades L Grange P Gaudin C Alexandre P Miossec 2007 A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab Arthritis Res Ther 9 R61 10.1186/ar2219 17597527
55. MC Genovese JD McKay EL Nasonov EF Mysler NA da Silva E Alecock T Woodworth JJ Gomez-Reino 2008 Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 58 2968 2980 10.1002/art.23940 1:CAS:528:DC%2BD1cXht12rur%2FJ 18821691
56. JS Smolen A Beaulieu A Rubbert-Roth C Ramos-Remus J Rovensky E Alecock T Woodworth R Alten 2008 Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 987 997 10.1016/S0140-6736(08)60453-5 1:CAS:528:DC%2BD1cXjs1Sltbc%3D 18358926 (Pubitemid 351392039)
57. E Choy N Sattar 2009 Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions Ann Rheum Dis 68 460 469 10.1136/ard.2008.101964 1:CAS:528:DC%2BD1MXkt1emsbY%3D 19286905
58. P Sambrook 2007 Tumour necrosis factor blockade and the risk of osteoporosis: back to the future Arthritis Res Ther 9 107 10.1186/ar2277 17850677 (Pubitemid 47354917)